Advertisement
Rapid CommunicationAccelerated Communication

Mdr1 Limits CYP3A Metabolism in Vivo

Lu-Bin Lan, James T. Dalton and Erin G. Schuetz
Molecular Pharmacology October 2000, 58 (4) 863-869; DOI: https://doi.org/10.1124/mol.58.4.863

Abstract

We determined whether the drug efflux protein P-glycoprotein (Pgp) could influence the extent of CYP3A-mediated metabolism of erythromycin, a widely used model substrate for CYP3A. We compared CYP3A metabolism of erythromycin (a Pgp substrate) using the erythromycin breath test in mice proficient and deficient ofmdr1 drug transporters. We first injectedmdr1(+/+) mice with [14C]N-methyl erythromycin and measured the rate of appearance of 14CO2 in the breath as a measure of hepatic CYP3A activity. Animals treated with CYP3A inducers or inhibitor showed accelerated or diminished14CO2 in the breath, respectively. The erythromycin breath test was next administered tomdr1a(−/−) and mdr1a/1b(+/+) and (−/−) mice. These animals had equivalent levels of immunoreactive CYP3A and CYP3A activity as measured by erythromycinN-demethylase activity in liver microsomes. Nevertheless, the rate of 14CO2 appearance in the breath showed no relationship with these measurements of CYP3A, but changed proportionally to expression of mdr1. The average breath test14CO2 area under the curves were 1.9- and 1.5-fold greater in mdr1a/1b(−/−) andmdr1a(−/−) mice, respectively, compared with (+/+) mice, and CERmax was 2-fold greater inmdr1a/1b(−/−) compared with (+/+) mice. We conclude that Pgp, by limiting intracellular substrate availability can be an important determinant of CYP3A metabolism of numerous medications that are substrates for CYP3A and Pgp.

Factors that contribute to interindividual variation in drug disposition influence drug toxicity, drug efficacy, and hence, therapeutic outcome. There is at least a 10-fold human variation in the systemic clearance of erythromycin (Watkins et al., 1985, 1990) and cyclosporin A (CsA). CYP3A is the exclusive P-450 involved in the N-demethylation of erythromycin, and the major CYP catalyzing the formation of CsA metabolites. Moreover, CYP3A has been estimated to metabolize 60% of all drugs (Wrighton et al., 1996). Because CYP3A expression varies 10- to 40-fold between humans (Watkins et al., 1985; Shimada and Guengerich, 1989), it has been proposed that differences in the clearance of drugs such as erythromycin and CsA can be explained by variation in hepatic CYP3A.

The “erythromycin breath test” (ERMBT) (Watkins et al., 1989;Watkins, 1991) was developed to phenotype the differences in hepatic CYP3A4 activity between humans. The ERMBT relies on the assumption that following i.v. administration of [14C]N-methyl erythromycin, CYP3A4 in the liver limits the rate of erythromycinN-demethylation. CYP3A4 demethylates [14C]N-methyl erythromycin, and at least half the radiolabeled carbon appears almost instantly in the breath as 14CO2 (Watkins, 1991, 1994). Thus, the rate of production of breath14CO2 following i.v. [14C]N-methyl erythromycin has been proposed as a standard assay for measuring hepatic CYP3A4 activity (Watkins et al., 1989; Watkins, 1994). The ERMBT also relies on the assumption that other process, such as cellular efflux of substrate, are not limiting.

However, it is now appreciated that P-glycoprotein (Pgp)-mediated transport of drugs out of cells is important in influencing intracellular drug concentration, and hence drug action. Pgp, the product of the mutidrug resistance gene MDR1 is abundantly expressed in liver and intestine (Van der Bliek et al., 1987) and effluxes many clinically important drugs. Indeed, we have shown that Pgp transports erythromycin and determines tissue levels of erythromycin in vivo (Schuetz et al., 1998).

Because Pgp and CYP3A are colocalized in intestine and liver and because Pgp can influence the disposition of drugs that are inducers and substrates of CYP3A, we speculated that there was a functional relationship between the Pgp transporter and CYP3A. Indeed, we demonstrated in animals and cells that Pgp directly influences the intrahepatic concentration of a CYP3A inducer, rifampin, and hence a pharmacological action of this drug in the cell, namely the extent of CYP3A induction (Schuetz et al., 1996). We have also shown that, under some circumstances, Pgp influences basal expression of CYP3A (Schuetz et al., 2000).

Based on our previous studies showing erythromycin as a Pgp substrate (Schuetz et al., 1998), we hypothesized that Pgp could limit the extent of CYP3A metabolism of erythromycin. To test this idea, we compared CYP3A metabolism of erthryomycin in vivo (using the ERMBT), in the presence or absence of Pgp using mdr1a1b(+/+) andmdr1a and mdr1a/1b(−/−) mice. Because the hepatic content of CYP3A was similar in mdr1a,mdr1a/1b(−/−) and (+/+) mice, variation in the ERMBT between these mice cannot be attributed to CYP3A, but is likely due to differences in Pgp. According to our hypothesis, the extent to which CYP3A can generate metabolites would be related to the expression of Pgp. The results from this investigation demonstrate that Pgp influences the rate and extent of CYP3A-mediated metabolism of erythromycin in liver in vivo.

Materials and Methods

Chemicals.

Dexamethasone (DEX), erythromycin, troleandomycin (TAO), dl-isocitric acid, isocitric dehydrogenase, and NADP were purchased from Sigma Chemical Company (St. Louis, MO). 3β-Hydroxy-20-oxopregn-5-ene-16 α-carbonitrile (PCN) was obtained from the Upjohn Company (Kalamazoo, MI). [14C]N-methyl erythromycin (54.0 mCi/mmol) was a gift from Dr. Paul Watkins (University of North Carolina).

Mice and Treatments.

Male mdr1a/b(+/+),mdr1a(−/−), and mdr1a/b(−/−) mice were purchased from Taconic Farms (Germantown, NY) and housed in the St. Jude Children's Research Hospital animal facility for a minimum of 3 weeks quarantine before use. DEX (300 mg/kg/day for 3 days), PCN (300 mg/kg/day for 3 days), or 0.9% NaCl were administered i.p. An additional group of mice was treated with dexamethasone (DEX; 300 mg/kg) for three days and then TAO (500 mg/kg) i.p. 2 h before the erythromycin breath test.

Erythromycin Breath Test.

The ERMBT was performed as described (Watkins et al., 1989; Watkins, 1991). Briefly, mice were anesthetized with metofane and injected i.v. with [14C]N-methyl erythromycin (1.0 μCi/100 g b.wt.) in 2.5% dextrose. The mice were then placed in a water-sealed polyurethane breath chamber with the air continuously drawn through a vapor trap (acetone and dry ice), then bubbled through a solution of acidic methanol (360 ml of methanol + 40 ml of 3 N HCl), and then through three gas washing bottles. The solutions to trap CO2 were prepared by mixing 540 ml of methanol, 820 ml of toluene, and 100 ml of Emulsifier-safe (Packard Bioscience Company, Meriden, CT) for 20 min under nitrogen. Phenethylamine (540 ml) (Aldrich Chemical Company, Inc., Milwaukee, WI) was then added with stirring (under nitrogen) for an additional 15 min. The three washing bottles in series each contained 30 ml of the mixture with 2 ml of toluene (first collection vessel containing 40 ml of mixture with 4 ml of toluene). Collection of breath was obtained at 5- or 20-min intervals over 30 min or over 4 h, respectively. After collection of breath, duplicate 4-ml samples from each point were analyzed for14C content by scintillation counting. The values were used to calculate the total14CO2 exhaled during the collection interval (Watkins et al., 1989; Watkins, 1991). After the final breath sample, animals were anesthetized with metofane and blood obtained by cardiac puncture into heparinized tubes. Livers were removed, washed with cold phosphate-buffered saline, and frozen in liquid nitrogen. The tissue was stored at −70°C until used for preparation of microsomes and analysis of radioactivity. Tissue radioactivity was measured as previously described (Schuetz et al., 1998).

Immunoblot Analysis.

Mouse liver microsomes were prepared (Schuetz et al., 2000) and 5 or 20 μg of protein was separated on 10% slab polyacrylamide gels and immunoblotted with polyclonal anti-CYP3A1 IgG followed by anti-goat IgG coupled with peroxidase and developed with diaminobenzidine tetrahydrochloride and hydrogen peroxide. CYP levels were quantified by comparing the densitometric values of a standard curve of purified rat CYP3A to the values obtained for microsomal samples of individual mdr1a/b(+/+),mdr1a(−/−), and mdr1a/b(−/−) mice livers analyzed on the same blots using the public domain NIH Image 1.62 program software (developed at the U.S. National Institutes of Health and available on the Internet at http://rsb.info.nih.gov/nih-image/).

Erythromycin N-Demethylation Assay.

[14C]N-Methyl erythromycinN-demethylation was investigated as described (Riley and Howbrook, 1998). Incubations consisted of 200 μl of microsomal protein (83.6 μg), erythromycin (∼0.1 μCi [14C]N-methyl erythromycin and 12.5 to 150 μg of nonradiolabeled erythromycin) and a NADPH regenerating system (7.5 mM isocitric acid, 5 mM magnesium sulfate, 1 mM NADP+, and 0.1 U of isocitrate dehydrogenase) were incubated at 37°C in a shaking water bath for 15 or 20 min, and the reaction was stopped by placing tubes on ice and adding 50 μl of 10% (v/v) trichloroacetic acid and centrifuged at 15,000gfor 10 min. Control incubations contained identical reagents but incubated on ice for 15 or 20 min. The supernatant was then applied to preconditioned (2 ml of methanol, 2 ml of water) Envi-Card solid-phase extraction columns (250-mg bed volume, Supelco, Sigma-Aldrich Co.). [14C]Erythromycin was retained on the column. [14C]HCHO was eluted with 2 volumes of water (2 × 500 μl), and eluted radioactivity quantified by liquid scintillation counting.

Pharmacokinetics.

Data were analyzed using noncompartmental pharmacokinetic analysis. CERmax, the maximum14CO2 exhalation rate, was determined from direct inspection of the exhalation rate versus time data. K breath, the terminal rate constant for the decline in the CO2 production rate, was calculated from the terminal slope of a plot of percentage of injected dose/min versus time from 100 to 240 min. The fraction of each dose converted to 14CO2 (in units of percentage of injected dose) was calculated as the area under the 14CO2 exhalation rate versus time curve using the linear trapezoid rule.

Statistics.

Four-hour data were analyzed using two-way ANOVA and 30-min data by using one-way ANOVA.

Results

Contribution of Mouse Liver CYP3A to ErythromycinN-Demethylase Activity.

We first determined whether CYP3A exclusively catalyzes erythromycin N-demethylation in mouse liver microsomes using an in vitro radiometric assay (Riley and Howbrook, 1998). This was necessary because there can be significant differences between CYP3As, e.g., even between CYP3A4 and CYP3A5, in the rate of product formation (Gillam et al., 1995). The evidence was strong that mouse liver CYP3A is the major enzyme catalyzing erythromycin N-demethylation. First, liver microsomes from mice treated with the CYP3A inducer DEX showed a significant increase in erythromycin N-demethylase activity over that in untreated control mice (see Fig. 4). Second, CYP3A activity in mouse liver microsomes (Fig. 1) was inhibited by preincubation with the CYP3A-specific inhibitor TAO (67%), ketoconazole (94%), or antibody to CYP3A (91%). By contrast, this activity was not inhibited by nonimmune IgG and was somewhat stimulated (Fig. 1), a result previously seen for other CYP450 reactions (Guengerich and Mason, 1979). Because the activity was almost totally inhibited by anti-CYP3A IgG, these results implicate mouse liver CYP3A as the predominant mouse liver enzyme catalyzing theN-demethylation of erythromycin.

Figure 4
Figure 4

Relationship between the in vivo erythromycinN-demethylation activity (ERMBT) and in vitro measures of CYP3A in liver microsomes from the identical mice. The AUC0–240 following i.v. [14C]N-methyl erythromycin was compared with the liver microsomal content of CYP3A measured in themdr1(+/+) animals treated with CYP3A inducers (A) and mice lacking the mdr1a and mdr1a/1b Pgp transporters (B). Each point represents a single mouse (○, control; ●, PCN; ▵, DEX). The values obtained frommdr1a/b(+/+) (⬡, control), mdr1a(−/−) (♦), and mdr1a/b(−/−) (■) mice. The AUC0–240 following i.v. [14C]N-methyl erythromycin was compared with the erythromycin demethylase activity measured in liver microsomes of the mdr1 (+/+) animals treated with CYP3A inducers (Table 1) (C) and mice lacking the mdr1a andmdr1a/1b transporters (Table 1) (D). Each point represents a single mouse (○, control; ●, PCN; ▵, DEX). The values obtained from mdr1a/b(+/+) (⬡, control),mdr1a(−/−) (♦), and mdr1a/b(−/−) (■) mice.

Figure 1
Figure 1

Effect of CYP3A inducers or inhibitors on erythromycin N-demethylase activity in mouse liver microsomes. Erythromycin N-demethylase activity was measured in liver microsomes from mdr1a/1b(+/+) control mice treated with NaCl (200 μl of 0.9%/mouse/day) for 3 days. Activities are expressed relative to the activity in control liver microsomes assigned a value of 100%. Some microsomes were preincubated with TAO (200 or 100 μM), ketoconazole (100 μM), polyclonal goat anti-CYP3A1 IgG (5 mg of IgG/mg of protein) or nonimmune (N-IgG) (5 mg of IgG/mg of protein). Data are depicted as means ± S.D. (n = at least two experiments performed in quadruplicate).

The ERMBT Is Influenced by Inducers and Inhibitors of CYP3A in Mice.

We used a procedure previously validated for administering the ERMBT to rats (Watkins et al., 1989; Watkins, 1991). Mice were pretreated with either NaCl or inducers of CYP3A, i.e., DEX or PCN. One additional group was pretreated with DEX and administered the CYP3A inhibitor TAO 2 h before the ERMBT. Mdr1(+/+) mice were then administered i.v. a trace dose of [14C]N-methyl erythromycin, immediately placed in the breath test chamber, and the rate of production of 14CO2 over time in the breath was measured by trapping the14CO2. The mouse ERMBT bore all signatures of CYP3A being rate-limiting in the reaction. CYP3A inducers DEX and PCN increased the maximum rate of exhalation of14CO2 in the breath (CERmax) by 1.5- and 1.7-fold, respectively, compared to NaCl-treated mice (Fig. 2A). AUC0–240 was also increased 1.5- to 1.8-fold by CYP3A inducer treatment (Table 1). Treatment of DEX-pretreated mice with the CYP3A inhibitor TAO for 2 h before the ERMBT decreased the rate of14CO2 exhalation in the breath to one-third of that observed in DEX-treated animals and one-half that observed in NaCl-treated mice (Fig. 2A, Table 1). The accelerated rate of 14CO2production in the breath of DEX- and PCN-treated compared with control mice disappeared after 1 to 2 h, suggesting there was accelerated depletion of the trace dose of substrate in these treated mice during the ERMBT. In rats, the ERMBT pharmacokinetic parameters were better approximated in inducer-treated animals when pharmacological doses of erythromycin were administered with [14C]N-methyl erythromycin (Watkins et al., 1989). Unfortunately, i.v. pharmacological doses of erythromycin proved fatal to untreated mdr1/1b(+/+) mice. Nevertheless, the induction and inhibition of the mouse ERMBT by CYP3A inducers and inhibitors bore the characteristics of a CYP3A catalyzed reaction.

Figure 2
Figure 2

Elimination of 14CO2 in the breath of mice following i.v. [14C]N-methyl erythromycin. A,mdr1(+/+) mice were injected i.p. with NaCl (●, 200 μl of 0.9%/mouse/day) or with CYP3A inducers DEX (▴, 300 mg/kg/day), or PCN (○, 300 mg/kg/day) for 3 days. In one group, mice treated i.p. with DEX (300 mg/kg/day) for 3 days were injected i.p. with TAO (▵, 500 mg/kg) 2 h before the ERMBT. B, elimination of14CO2 in the breath ofmdr1a/b(+/+), mdr1a(−/−), andmdr1a/b(−/−) mice administered the ERMBT. For the ERMBT each mouse was given trace [14C]N-methyl erythromycin (0.1 μCi/100 g b.wt.). 14CO2 in breath was determined at 20-min intervals. Data are depicted as means ± S.D. (n ≥ 3).

View this table:
Table 1

Pharmacokinetics of breath 14CO2 after injection of [14C]N-methyl erythromycin

Mdr1 Genotype Is Directly Correlated with the ERMBT.

To directly examine the role of Pgp in the ERMBT, we administered i.v. [14C]N-methyl erythromycin tomdr1a (−/−), mdr1a/1b(−/−) and (+/+) mice. The percentage of the i.v. [14C]N-methyl erythromycin dose converted to 14CO2 (as measured by AUC0–240) was markedly increased in animals lacking the mdr1 transporters (Fig. 2B) with a rank order ofmdr1a/1b(−/−) > mdr1a(−/−) > (+/+) mice (Table 1, Fig. 2B) indicating that both mdr1a andmdr1b in liver affected the breath test results. These differences in ERMBT AUC in mdr1a andmdr1a/1b(−/−) compared to (+/+) mice were statistically significant (P < .0001) (Table 1). The CERmax was also 2-fold greater in themdr1a/1b(−/−) mice compared to the (+/+) mice. However,K breath (the terminal rate constant for the decline in the CO2 production rate) was not different among the mdr1 genotypes.

In humans, the ERMBT is administered over 20 or 60 min after i.v. [14C]N-methyl erythromycin (Watkins et al., 1989; Kinirons et al., 1999). To determine whether the rate of erythromycin demethylation is greater in the animals lacking Pgp at an earlier time point, we administered the ERMBT to mice over 0 to 30 min after i.v. [14C]N-methyl erythromycin. As observed in studies conducted over 4 h, the AUC0–30 were significantly different between animal groups. The AUC0–30 min was 1.6-fold higher in mdr1a(−/−) mice, compared to (+/+) mice. Similarly, the CERmax values were 1.67-fold higher in the mdr1a(−/−) mice compared to (+/+) mice.

We next compared the impact of mdr1 gene disruption on [14C]-erythromycin (reflecting both erythromycin and the CYP3A cleaved radiolabeled14C atom) tissue concentrations at 30 min and 4 h and compared these values to the percentage of the dose converted to 14CO2 (AUC) (Table 2). The 1.5-fold increase in hepatic and plasma radioactivity in mdr1a(−/−) mice was proportional to the 1.5-fold increase in the14CO2 AUC in these same mice. Thus, Pgp membrane transport processes were influencing the hepatic concentration of the CYP3A substrate erythromycin and its subsequent rate of CYP3A-mediated demethylation.

View this table:
Table 2

Ratio of radioactivity (ng/g of tissue) and AUC [14C]CO2 in mdr1a (−/−),mdr1a/1b(−/−) mice compared to mdr1a(+/+) mice following [14C]N-methyl erythromycin injection

We recently demonstrated, in mdr1(−/−) mice housed in the United States, that hepatic CYP3A expression is similar or even lower to that than in mdr1a(+/+) mice (Schuetz et al., 2000). However, we also demonstrated that environmental and/or physiological challenges to the mdr1(−/−) mice can alter CYP expression. Therefore, we quantitated the hepatic content of CYP3A on immunoblots of liver microsomes from mice administered the ERMBT. The specific content of immunoreactive CYP3A in the mdr1a/1b, mdr1a(−/−) mice was similar (or even lower) than that inmdr1a/1b(+/+) mice (Fig. 3, Table 1).

Figure 3
Figure 3

Immunoquantitation of CYP3A in the livers of mice given the ERMBT. Liver microsomes were prepared from animals who received the ERMBT over 30 min or 4 h and 20 μg resolved for 2 h on 10% polyacrylamide gel electrophoresis. The gel was stopped, and purified CYP3A1 (0.25 to 2 pmol) was loaded in duplicate and the gel run for an additional 2 h, blotted to nitrocellulose and developed with anti-CYP3A IgG. The concentration of CYP3A proteins was calculated in the mouse liver microsomes from interpolation with the integrated density of the duplicate CYP3A standard curves.

Next we compared in the identical mice the in vivo ERMBT results to the in vitro immunocontent of hepatic CYP3A and associated erythromycinN-demethylase activity in their liver microsomes. In control, PCN-, and DEX-treated mdr1(+/+) mice there was excellent correlation between the AUC0–240 and the hepatic content of CYP3A (r 2 = 0.932) (Fig. 4A) and the liver microsomal erythromycin demethylase activity (r 2= 0.841) (Fig. 4C). Thus, under these conditions CYP3A is limiting the ERMBT. However, using mdr1a, mdr1a/1b(−/−) and (+/+) mice we found no correlation between the in vivo ERMBT results and in vitro hepatic CYP3A immunocontent (r 2 = 0.057) (Fig. 4B) or the microsomal erythromycin demethylase activity in the corresponding liver microsomes (r 2 = 0.092) (Fig. 4D).

Discussion

Drug transport across biological membranes is a critical determinant of drug action. With the growing recognition that many CYP3A substrates are also Pgp substrates, the role of Pgp in CYP3A metabolism must be analyzed. Thus, the focus of this research was to test the hypothesis that Pgp transport influenced CYP3A metabolism. We used the ERMBT to test this idea assuming the two major determinants of the ERMBT are the activity of CYP3A and cellular bioavailability of erythromycin. The latter idea is based on our previous findings that Pgp affects the tissue disposition of erythromycin (Schuetz et al., 1998). We predicted that Pgp, by limiting the hepatic erythromycin concentration, would influence the amount of CYP3A-generated metabolites. This hypothesis is based on the mathematical relationship describing the rate of conversion of erythromycin to theN-demethylated metabolite as v =V max[S]/K m + [S]. We know from our studies that mdr1a(−/−) andmdr1a/1b(+/+) and (−/−) mice have the same amount of hepatic CYP3A protein and activity (V max/K m, intrinsic clearance, is likely the same). Thus, any difference in the rate of erythromycin metabolism between these mice will be dependent on the intracellular concentration of the substrate and, thus, Pgp.

Although there have been several reports in the literature that suggest Pgp might influence CYP3A-dependent metabolism in vivo, these in vitro studies have largely used Caco-2 cells, which are problematic because of low levels of CYP3A4 and expression of multiple drug efflux transporters (Gan et al., 1996; Raeissi et al., 1999;Hochman et al., 2000). To determine whether the ERMBT was influenced by Pgp, we used mice genetically modified to express either one or both mdr1 transporters. Our results indicate that Pgp and CYP3A are functionally associated because the extent to which CYP3A metabolized erythromycin, as measured by the breath14CO2 AUC, was related to the gene dose of the mdr1 alleles in these mice. These results support the idea that CYP3A is not the single rate-limiting determinant of the ERMBT, but that hepatic Pgp is also rate limiting in the conversion of [14C]N-methyl erythromycin to 14CO2 in the breath and that the ERMBT is measuring both hepatic Pgp and CYP3A. This finding emphasizes the critical role that Pgp plays in hepatic drug elimination even for drugs that are extensively metabolized. These findings extend our understanding of the interactions between CYP3A4 and Pgp expression in drug metabolism.

The 1.5- to 1.8-fold induction of CERmaxfollowing DEX or PCN was less than the 6- to 8-fold induction of hepatic CYP3A protein (Table 1) that was observed following these inducers. It is possible that DEX induction of liver Pgp decreases the amount of methyl erythromycin available to CYP3A, resulting in a smaller increase in the rate of14CO2 exhalation in the breath of DEX-pretreated mice. Indeed the hepatic concentration of [14C]N-methyl erythromycin was greater in control versus DEX-treated mice (70.3 ± 11.6 versus 40.8 ± 9.9 pmol [14C]N-methyl erythromycin/g of liver, respectively), and DEX can increase Pgp levels in rodent liver (Salphati and Benet, 1998).

There are two possible explanations for the observed changes in AUC: 1) altered clearance of the metabolite (14HCHO) or 2) an increased proportion of erythromycin that is converted to14CO2. The terminal rate constant for the decline in the CO2 production rate (K breath) did not change. In fact,K breath did not differ between any of treatment groups, including animals treated with DEX, PCN, or TAO. One might expect K breath to change with changes in hepatic CYP3A activity. However, this would only be true if the rate constant for erythromycin metabolism by CYP3A is less than the rate constant describing CO2 production from formaldehyde and if demethylation were a major pathway for erythromycin elimination in mice. The fact that K breathdid not differ between any of our treatment groups might indicate that the rate of erythromycin metabolism by CYP3A is significantly faster than CO2 production from formaldehyde, and thatK breath is a poor measure of CYP3A activity in mice. Alternatively, if CO2 production from formaldehyde is not rate limiting, K breathreflects elimination of erythromycin from the blood and that is relatively unchanged by any of the treatments in mice. Thus, it appears reasonable to conclude that the increased14CO2 AUC in mice lacking Pgp is due to a greater fraction of labeled erythromycin being metabolized. Because the amount of CYP3A protein and associated catalytic activity is indistinguishable between the mdr1genotypes, the differences in14CO2AUC0–240 and AUC0–30 inmdr1a/1b and mdr1a(−/−) compared to (+/+) mice indicates Pgp is working to control the amount of drug available for metabolism.

There is evidence that Pgp similarly influences the extent of CYP3A-mediated metabolism of erythromycin in humans. The ERMBT, has consistently found that women have higher CYP3A activity than men (Austin et al., 1980). However, immunoquantitation of CYP3A and analysis of CYP3A-mediated activity in liver microsomes from males and females has failed to identify a gender difference in CYP3A expression or activity (Shimada et al., 1994). Although a number of explanations are possible (e.g., volume of distribution), our report (Schuetz et al., 1995) of a gender difference in the hepatic expression of human Pgp (men have a significantly higher content of Pgp then women) could explain the in vitro/in vivo discrepancy in the ERMBT. Since men have higher Pgp then women, men would effectively attain lower intrahepatic levels of erythromycin, generate less erythromycin metabolite, have a lower erythromycin breath test, and thus an apparent lower level of hepatic CYP3A compared with women. This idea is supported by evidence that clearance of i.v. midazolam, a CYP3A substrate, but non-Pgp substrate (Kim et al., 1999), did not correlate with the ERMBT in measuring hepatic CYP3A activity and shows no gender difference (Kinirons et al., 1999).

Our study differs significantly from others examining the influence of Pgp on drug pharmacokinetics. Two recent studies reported thatmdr1 genotype does not effect CYP3A-mediated metabolism of midazolam, testosterone 6β-hydroxylation, nifedipine oxidation, or biotransformation of ivermectin or CsA (Kwei et al., 1999; Perloff et al., 1999). However, these studies were either performed in liver microsomes that do not contain Pgp, or only determined parent drug. Two other studies have examined metabolites of drugs inmdr1a(+/+) and (−/−) mice (van Asperen et al., 1996;1999). These reports found higher accumulation of doxorubicin and vinblastine metabolites in the livers of mdr1a(−/−) compared to (+/+) mice 4 to 24 h after i.v. dosing (van Asperen et al., 1996, 1999). However, although the increased amount of these metabolites would be consistent with an increase in the rate and extent of drug metabolism, it is impossible to distinguish in these kinds of studies to what extent either increased metabolism, decreased further metabolism, or decreased efflux of metabolite contributes to the total amount of hepatic metabolite. In contrast, the ERMBT suffers from none of the aforementioned problems. Indeed, with the ERMBT CYP3A-mediatedN-demethylation of [14C]N-methyl erythromycin results in approximately half the radiolabeled carbon atoms appearing almost immediately in the breath as14CO2 (Watkins, 1991). Thus, the ERMBT offers the unique advantage of being a “real time” metabolism assay, allowing instantaneous measurement of hepatic CYP3A activity in the liver, and providing a better test for a functional relationship between Pgp and CYP3A.

Our identification of multiple levels of interaction between CYP3A and Pgp (Schuetz et al., 1996, 2000) demonstrates that the overall pharmacology of shared Pgp/CYP3A substrates needs to be reevaluated from the context of a role for Pgp. An additional implication of this study is that because Pgp transport exerts greater control over CYP3A metabolism than previously realized, induction or inhibition Pgp will also have consequences to CYP3A-mediated metabolism. Thus, there needs to be stronger emphasis on understanding the influence of Pgp to drug metabolism. In addition, although CYP3A metabolism of erythromycin in the liver is substrate limited, because the kinetics of interaction of any substrate with Pgp and CYP3A4 will be different it will be necessary to compare on a substrate-by-substrate basis (and at higher doses) whether Pgp membrane transport processes limit CYP3A4-mediated metabolism. However, it is not feasible or practical to test the interactions of most Pgp and CYP3A substrates using themdr1(−/−) mice, in part due to the issues discussed above. However, we have recently generated a cellular system (Brimer et al., 2000) to model the interactions of human MDR1/Pgp and CYP3A4, which should allow a rapid assessment of whether Pgp influences the rate and extent of CYP3A4-mediated metabolism of other drugs.

A broader implication of this work is that Pgp could limit metabolism by other CYPs. For example, although CYP3A metabolizes the Pgp substrate taxol, the principal taxol biotransformation product in humans is generated by another CYP (Harris et al., 1994). Thus, Pgp membrane transport controlling the rate of CYP3A metabolism is likely to be a paradigm for additional Pgp-drug metabolism interactions.

The finding that the ERMBT measures both Pgp and CYP3A has several clinical implications. First, it is possible that, in the future, the ERMBT could be used simultaneously with some measure of plasma erythromycin to determine hepatic Pgp levels in humans. Second, for drugs, like erythromycin, that are substrates for both CYP3A4 and Pgp (e.g., CsA, indinavir) (Schinkel et al., 1995; Kim et al., 1998, 1999), the ERMBT may be the preferred assay to use for predicting their systemic clearances. Indeed, the ERMBT predicts the steady-state trough blood levels of CsA, a CYP3A4 and Pgp substrate (Watkins, 1994). Thus, our results also suggest that the previously described human variation in CsA clearance, explained solely by hepatic CYP3A4 content (as measured by the ERMBT), may also be due to human variation in hepatic Pgp. We conclude that Pgp, by limiting substrate concentration, is also an important determinant of the extent of CYP3A metabolites formed in the cell. Therefore, it is likely that individual variation in the hepatic content of Pgp and CYP3A contributes to the overall interindividual variation seen in the disposition and therapeutic efficacy of shared substrates.

Acknowledgment

We thank John Schuetz for thoughtful comments.

Footnotes

    • Received April 21, 2000.
    • Accepted June 5, 2000.

  • Send reprint requests to: Dr. Erin Schuetz, Dept. of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105. E-mail:erin.schuetz{at}stjude.org

  • This work was supported by National Institutes of Health Research Grants ES08658 and P30 CA21765 (to E.G. S.), a grant from the St. Francis of Assisi Foundation of Memphis (to J.T.D.), the Center of Excellence Grant from the State of Tennessee, and by the American Lebanese Syrian Associated Charities (ALSAC).

Abbreviations

CsA
cyclosporin A
Pgp
P-glycoprotein
ERMBT
erythromycin breath test
CERmax
the maximum14CO2 exhalation rate
CYP
cytochrome P-450
PCN
3β-hydroxy-20-oxopregn-5-ene-16 α-carbonitrile
TAO
troleandomycin
DEX
dexamethasone
AUC
area under curve

References

  1. ↵
    1. Austin KL,
    2. Mather LE,
    3. Philpot CR, and
    4. McDonald PJ
    (1980) Intersubject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol 10:273–279.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Brimer C,
    2. Dalton JT,
    3. Zhu Z,
    4. Schuetz J,
    5. Yasuda K,
    6. Vanin E,
    7. Relling MV,
    8. Lu Y, and
    9. Schuetz E
    (2000) Creation of polarized cells co-expressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein. Pharm Res 17:803–810.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Gan L-S,
    2. Moseley MA,
    3. Khosla B,
    4. Augustijns PF,
    5. Bradshaw TP,
    6. Hendren RW, and
    7. Thakker DR
    (1996) CYP3A-like cytochrome P-450 mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab Dispos 24:344–349.
    OpenUrlAbstract
  4. ↵
    1. Gillam EMJ,
    2. Guo Z,
    3. Ueng Y-F,
    4. Yamazaki H,
    5. Cock I,
    6. Reilly PE,
    7. Hooper WD, and
    8. Guengerich FP
    (1995) Expression of cytochrome P450 3A5 in Escherichia coli: Effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch Biochem Biophys 317:374–384.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Guengerich FP and
    2. Mason PS
    (1979) Immunologic comparison of extrahepatic cytochromes P-450. Mol Pharmacol 15:154–164.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Harris JW,
    2. Rahman A,
    3. Kim B-R,
    4. Guengerich FP, and
    5. Collins JM
    (1994) Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P4503A4 and an unknown P450 enzyme. Cancer Res 54:4026–4035.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Hochman JH,
    2. Chiba M,
    3. Nishime J,
    4. Yamazaki M, and
    5. Lin JH
    (2000) Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-4503A4. J Pharmacol Exp Ther 292:310–318.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Kim RB,
    2. Fromm MF,
    3. Wandel C,
    4. Leake B,
    5. Wood AJJ,
    6. Roden DM, and
    7. Wilkinson GR
    (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289–294.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Kim RB,
    2. Wandel C,
    3. Leake B,
    4. Cvetkovic M,
    5. Fromm MF,
    6. Dempsey PJ,
    7. Roden MM,
    8. Belas F,
    9. Chaudhary AK,
    10. Roden DM,
    11. Wood AJJ, and
    12. Wilkinson GR
    (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (N Y) 16:408–414.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Kinirons MT,
    2. O'Shea D,
    3. Kim RB,
    4. Groopman JD,
    5. Thummel KE,
    6. Wood AJJ, and
    7. Wilkinson GR
    (1999) Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 66:224–231.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Kwei GY,
    2. Alvaro RF,
    3. Chen Q,
    4. Jenkins HJ,
    5. Hop CEAC,
    6. Keohane CA,
    7. Strauss JR,
    8. Wang RW,
    9. Wang TR,
    10. Pippert TR, and
    11. Umbenhauer DR
    (1999) Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab Dispos 27:581–587.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Perloff MD,
    2. von Moltke LL,
    3. Cotreau MM, and
    4. Greenblatt DJ
    (1999) Unchanged cytochrome P450 3A (CYP3A) Expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(−/−) mouse liver microsomes. Biochem Pharmacol 57:1227–1232.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Raeissi SD,
    2. Hidalgo IJ,
    3. Segura-Aguilar J, and
    4. Artursson P
    (1999) Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers. Pharm Res 16:625–632.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Riley RJ and
    2. Howbrook D
    (1998) In vitro analysis of the activity of the major human hepatic CYP enzyme (CYP3A4) using [N-methyl-14C]-erythromycin. J Pharmacol Toxicol Methods 38:189–193.
    OpenUrlCrossRef
  15. ↵
    1. Salphati L and
    2. Benet LZ
    (1998) Modulation of P-glycoprotein expression by cytochrome P4503A inducers in male and female rat livers. Biochem Pharmacol 55:389–395.
    OpenUrl
  16. ↵
    1. Schinkel AH,
    2. Wagenaar E,
    3. van Deemter L,
    4. Mol C, and
    5. Borst P
    (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J Clin Invest 96:1698–1705.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Schuetz EG,
    2. Furuya KN, and
    3. Schuetz JD
    (1995) Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 275:1011–1018.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Schuetz EG,
    2. Schinkel AH,
    3. Relling MV, and
    4. Schuetz JD
    (1996) P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 93:4001–4005.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Schuetz EG,
    2. Umbenhauer DR,
    3. Yasuda K,
    4. Brimer C,
    5. Nguyen L,
    6. Relling MV,
    7. Schuetz JD, and
    8. Schinkel AH
    (2000) Altered expression of hepatic cytochromes P450 in mice deficient in one or more mdr1 genes. Mol Pharmacol 57:188–197.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Schuetz EG,
    2. Yasuda K,
    3. Arimor K, and
    4. Schuetz JD
    (1998) Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene. Arch Biochem Biophys 350:340–347.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Shimada T and
    2. Guengerich FP
    (1989) Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc Natl Acad Sci USA 86:462–465.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Shimada T,
    2. Yamazake H,
    3. Mimura M,
    4. Inui Y, and
    5. Guengerich FP
    (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. van Asperen J,
    2. Schinkel AH,
    3. Beijnen JH,
    4. Nooijen WJ,
    5. Borst P, and
    6. van Tellingen O
    (1996) Altered pharmacokinetics of vinblastine in mdr1a P-glycoprotein-deficient mice. J Natl Cancer Inst 88:994–999.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. van Asperen J,
    2. van Tellingen O,
    3. Tijssen F,
    4. Schinkel AH, and
    5. Beijnen JH
    (1999) Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br J Cancer 79:108–113.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Van der Bliek AM,
    2. Baas R,
    3. Ten Houte de Lange T,
    4. Kooiman PM,
    5. Van der Velde-Koerts T, and
    6. Borst P
    (1987) The human mdr3 gene encodes a novel P-glycoprotein homologue and gives rise to alternatively spliced mRNAs in liver. EMBO J 6:3325–3331.
    OpenUrlPubMed
  26. ↵
    1. Watkins PB
    (1991) Breath tests as noninvasive assays of P450s. Methods Enzymol 206:517–522.
    OpenUrlPubMed
  27. ↵
    1. Watkins PB
    (1994) Noninvasive tests of CYP3A enymes. Pharmacogenetics 4:171–184.
    OpenUrlPubMed
  28. ↵
    1. Watkins PB,
    2. Hamilton TA,
    3. Annesley TM,
    4. Ellis CN,
    5. Kolars JC, and
    6. Voorhees JJ
    (1990) The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther 48:120–129.
    OpenUrlPubMed
  29. ↵
    1. Watkins PB,
    2. Wrighton SA,
    3. Maurel P,
    4. Schuetz EG,
    5. Mendez-Picon G,
    6. Parker GA, and
    7. Guzelian PS
    (1985) Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci USA 82:6310–6314.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Wrighton SA,
    2. Vandenbranden M, and
    3. Ring BJ
    (1996) The human drug metabolizing cytochromes P450. J Pharmacokinetics Biopharm 24:461–473.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Watkins PB,
    2. Murray SA,
    3. Winkelman LG,
    4. Heuman DM,
    5. Wrighton SA, and
    6. Guzelian PS
    (1989) Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J Clin Invest 83:688–697.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Rapid CommunicationAccelerated Communication

Mdr1 Limits CYP3A Metabolism in Vivo

Lu-Bin Lan, James T. Dalton and Erin G. Schuetz
Molecular Pharmacology October 1, 2000, 58 (4) 863-869; DOI: https://doi.org/10.1124/mol.58.4.863
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement